Resistance to Cetuximab in Colorectal Cancer
Author Information
Author(s): Cappuzzo F, Varella-Garcia M, Finocchiaro G, Skokan M, Gajapathy S, Carnaghi C, Rimassa L, Rossi E, Ligorio C, Di Tommaso L, Holmes A J, Toschi L, Tallini G, Destro A, Roncalli M, Santoro A, Jänne P A
Primary Institution: Istituto Clinico Humanitas IRCCS, Milan University
Hypothesis
The impact of KRAS mutations on cetuximab sensitivity in EGFR FISH-positive colorectal cancer patients has not been previously investigated.
Conclusion
KRAS mutations are associated with cetuximab failure in EGFR FISH+ metastatic colorectal cancer, even if they do not completely prevent response.
Supporting Evidence
- KRAS mutations were found in 52.5% of patients and negatively affected response in EGFR FISH+ patients.
- Patients with EGFR FISH+/KRAS mutations had a significantly lower response rate compared to those with KRAS wild type.
- Patients overexpressing IGF1R had significantly longer survival than those with low IGF1R expression.
Takeaway
This study looked at how certain gene mutations affect the effectiveness of a cancer treatment called cetuximab in patients with colorectal cancer. It found that a specific mutation (KRAS) makes the treatment less likely to work.
Methodology
The study analyzed KRAS, BRAF, PI3KCA, MET, and IGF1R mutations in 85 metastatic colorectal cancer patients treated with cetuximab-based therapy.
Potential Biases
Potential biases may arise from the retrospective nature of the analyses and the selection criteria for patients.
Limitations
The study's findings may not be generalizable due to the specific patient population and the rarity of some mutations.
Participant Demographics
The majority of patients were male (63.5%) with a median age of 63.2 years.
Statistical Information
P-Value
0.04
Statistical Significance
p=0.04
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website